Olfr799 is a member of the olfactory receptor (OR) family, which plays a critical role in the sense of smell. As a G protein-coupled receptor (GPCR), Olfr799 is involved in detecting specific odorant molecules, a process essential for olfactory perception. The activation of Olfr799, like other olfactory receptors, typically occurs through the binding of odorant molecules, leading to conformational changes in the receptor structure. These changes facilitate the coupling with G proteins, which then initiate a series of intracellular signaling events that translate the chemical signal into a neuronal response. The specific ligands and broader physiological functions of Olfr799 are not entirely characterized, mirroring the complexity inherent in the study of olfactory receptors, which often exhibit highly specific ligand affinities. The activation mechanisms of Olfr799 are influenced by the cellular environment and the presence of various signaling molecules. A key regulatory pathway in GPCR function is the cyclic adenosine monophosphate (cAMP) signaling pathway. cAMP serves as a secondary messenger within cells and regulates a wide range of cellular functions, including GPCR signaling. The synthesis of cAMP is catalyzed by adenylate cyclase, which converts ATP into cAMP in response to external stimuli. The resulting cAMP can activate protein kinase A (PKA), leading to phosphorylation of various proteins, including GPCRs themselves. This phosphorylation can alter the receptor's responsiveness to ligands, affecting its activation dynamics. Additionally, cAMP can interact with other signaling pathways that intersect with GPCR signaling, thereby modulating the activity of receptors such as Olfr799.
Phosphodiesterases (PDEs), responsible for cAMP degradation, are crucial in regulating its intracellular concentration. Inhibiting PDEs can lead to increased cAMP levels within the cell, indirectly affecting GPCR signaling. This increase in cAMP, resulting from PDE inhibition, can indirectly modulate the activity of Olfr799 through various mechanisms, including changes in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Furthermore, compounds that directly increase cAMP levels, such as adenylate cyclase activators or β-adrenergic receptor agonists, can also indirectly affect the activity of Olfr799. These interactions underscore the complexity of GPCR regulation and highlight the potential of various chemical compounds to modulate the activity of receptors like Olfr799 indirectly. In summary, the study of Olfr799 activation provides essential insights into the olfactory system and the broader role of GPCRs in physiological and sensory processes. The intricate interplay between different cellular components and signaling molecules, as well as the potential for modulation by external compounds, emphasizes the complexity and significance of these receptors in sensory perception and cellular communication.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a β-adrenergic agonist, increases intracellular cAMP via adenylate cyclase activation. This cAMP increase could indirectly modulate Olfr799 signaling pathways, enhancing receptor activation and signal transduction. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, raises cAMP and cGMP levels, potentially influencing Olfr799 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine stimulates α and β-adrenergic receptors, increasing cAMP via adenylate cyclase. This cAMP surge could indirectly affect Olfr799 activation, potentially enhancing its activity through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a phosphodiesterase 4 (PDE4) inhibitor, leads to increased cAMP levels. Elevated cAMP may enhance Olfr799 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide, a selective PDE3 inhibitor, increases intracellular cAMP, potentially influencing Olfr799 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol, a β2-adrenergic agonist, raises cAMP levels via adenylate cyclase activation. This increase might boost Olfr799 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr799 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr799 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr799 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy. | ||||||